+

WO2002102990A3 - Fibroblast growth factor and nucleic acid encoding same - Google Patents

Fibroblast growth factor and nucleic acid encoding same Download PDF

Info

Publication number
WO2002102990A3
WO2002102990A3 PCT/US2002/019400 US0219400W WO02102990A3 WO 2002102990 A3 WO2002102990 A3 WO 2002102990A3 US 0219400 W US0219400 W US 0219400W WO 02102990 A3 WO02102990 A3 WO 02102990A3
Authority
WO
WIPO (PCT)
Prior art keywords
fgf
nucleic acid
growth factor
acid encoding
fibroblast growth
Prior art date
Application number
PCT/US2002/019400
Other languages
French (fr)
Other versions
WO2002102990A8 (en
WO2002102990A2 (en
Inventor
Richard A Shimkets
Michael E Jeffers
Sudhirdas K Prayaga
Ferenc L Boldog
Meijia Yang
Catherine E Burgess
Elma R Fernandes
John L Herrmann
William J Larochelle
Henri S Lichenstein
Linda Gorman
Mei Zhong
Muralidhara Padigaru
Carol E A Pena
John P Ii Alsobrook
Denise M Lepley
Daniel K Rieger
William M Grosse
Original Assignee
Curagen Corp
Richard A Shimkets
Michael E Jeffers
Sudhirdas K Prayaga
Ferenc L Boldog
Meijia Yang
Catherine E Burgess
Elma R Fernandes
John L Herrmann
William J Larochelle
Henri S Lichenstein
Linda Gorman
Mei Zhong
Muralidhara Padigaru
Carol E A Pena
John P Ii Alsobrook
Denise M Lepley
Daniel K Rieger
William M Grosse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Richard A Shimkets, Michael E Jeffers, Sudhirdas K Prayaga, Ferenc L Boldog, Meijia Yang, Catherine E Burgess, Elma R Fernandes, John L Herrmann, William J Larochelle, Henri S Lichenstein, Linda Gorman, Mei Zhong, Muralidhara Padigaru, Carol E A Pena, John P Ii Alsobrook, Denise M Lepley, Daniel K Rieger, William M Grosse filed Critical Curagen Corp
Priority to JP2003506444A priority Critical patent/JP2005500035A/en
Priority to CA002446285A priority patent/CA2446285A1/en
Priority to EP02746584A priority patent/EP1401855A4/en
Publication of WO2002102990A2 publication Critical patent/WO2002102990A2/en
Publication of WO2002102990A3 publication Critical patent/WO2002102990A3/en
Publication of WO2002102990A8 publication Critical patent/WO2002102990A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides FGF-CX, a novel isolated polypeptide, as well as a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FGF-CX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as other uses.
PCT/US2002/019400 2001-06-15 2002-06-17 Fibroblast growth factor and nucleic acid encoding same WO2002102990A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003506444A JP2005500035A (en) 2001-06-15 2002-06-17 Novel fibroblast growth factor and nucleic acid encoding it
CA002446285A CA2446285A1 (en) 2001-06-15 2002-06-17 Fibroblast growth factor and nucleic acid encoding same
EP02746584A EP1401855A4 (en) 2001-06-15 2002-06-17 Novel fibroblast growth factor and nucleic acids encoding same

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US29844101P 2001-06-15 2001-06-15
US60/298,441 2001-06-15
US31644601P 2001-08-31 2001-08-31
US60/316,446 2001-08-31
US35959402P 2002-02-26 2002-02-26
US60/359,594 2002-02-26
US38517302P 2002-05-31 2002-05-31
US60/385,173 2002-05-31

Publications (3)

Publication Number Publication Date
WO2002102990A2 WO2002102990A2 (en) 2002-12-27
WO2002102990A3 true WO2002102990A3 (en) 2003-08-28
WO2002102990A8 WO2002102990A8 (en) 2003-12-24

Family

ID=29741032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019400 WO2002102990A2 (en) 2001-06-15 2002-06-17 Fibroblast growth factor and nucleic acid encoding same

Country Status (4)

Country Link
EP (1) EP1401855A4 (en)
JP (1) JP2005500035A (en)
CA (1) CA2446285A1 (en)
WO (1) WO2002102990A2 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054813A2 (en) * 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2001007595A2 (en) * 1999-07-27 2001-02-01 Curagen Corporation Novel fibroblast growth factor and nucleic acids encoding same
WO2001031008A2 (en) * 1999-10-22 2001-05-03 Chiron Corporation Human and rat fgf-20 genes and gene expression products
WO2001068854A2 (en) * 2000-03-13 2001-09-20 Amgen, Inc. Fibroblast growth factor-like molecules and uses thereof
WO2001092522A2 (en) * 2000-06-01 2001-12-06 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
US20020001825A1 (en) * 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
WO2002002625A2 (en) * 2000-07-03 2002-01-10 Curagen Corporation Novel fibroblast growth factors and nucleic acids encoding same
WO2002024234A2 (en) * 2000-09-20 2002-03-28 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365793A2 (en) * 2000-11-06 2003-12-03 Curagen Corporation Treatment of inflammatory bowel disease using growth factors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054813A2 (en) * 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2001007595A2 (en) * 1999-07-27 2001-02-01 Curagen Corporation Novel fibroblast growth factor and nucleic acids encoding same
WO2001031008A2 (en) * 1999-10-22 2001-05-03 Chiron Corporation Human and rat fgf-20 genes and gene expression products
WO2001068854A2 (en) * 2000-03-13 2001-09-20 Amgen, Inc. Fibroblast growth factor-like molecules and uses thereof
US20020001825A1 (en) * 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
WO2001092522A2 (en) * 2000-06-01 2001-12-06 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
WO2002002625A2 (en) * 2000-07-03 2002-01-10 Curagen Corporation Novel fibroblast growth factors and nucleic acids encoding same
WO2002024234A2 (en) * 2000-09-20 2002-03-28 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BANGE J. ET AL.: "Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 allele", CANCER RESEARCH, vol. 62, 1 February 2002 (2002-02-01), pages 840 - 847, XP002963936 *
BIKFALVI A. ET AL.: "Biological roles of fibroblast growth factor-2", ENDOCRINE REVIEWS, vol. 18, no. 1, February 1997 (1997-02-01), pages 26 - 45, XP002963934 *
KIRIKOSHI H. ET AL.: "Molecular cloning and characterization of human FGF-20 on chromosome 8p21.3-p22", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 274, no. 2, 2 August 2002 (2002-08-02), pages 337 - 343, XP002164265 *
OHMACHI S. ET AL.: "FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 277, no. 2, 22 October 2000 (2000-10-22), pages 355 - 360, XP002164264 *
See also references of EP1401855A4 *
WONG L.C. ET AL.: "Novel SNP at the common primer site of exon IIIa of FGFR2 gene causes error in molecular diagnosis of craniosynostosis syndrome", AMERICAN JOURNAL OF MEDICAL GENETICS, vol. 102, no. 3, 15 August 2001 (2001-08-15), pages 282 - 285, XP002963935 *

Also Published As

Publication number Publication date
CA2446285A1 (en) 2002-12-27
EP1401855A4 (en) 2004-12-22
WO2002102990A8 (en) 2003-12-24
JP2005500035A (en) 2005-01-06
WO2002102990A2 (en) 2002-12-27
EP1401855A2 (en) 2004-03-31

Similar Documents

Publication Publication Date Title
WO2001007595A3 (en) Novel fibroblast growth factor and nucleic acids encoding same
WO2000058473A3 (en) Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2001092523A3 (en) Human polynucleotides and polypeptides encoded thereby
WO2001036645A3 (en) Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same
WO2001090366A3 (en) Human polynucleotides and polypeptides encoded thereby
WO2000053742A3 (en) Polynucleotides and proteins encoded thereby
WO2001049729A8 (en) Novex polypeptides, nucleic acids encoding same and their diagnostic and therapeutic use
WO2002066647A3 (en) Type 2 ctokine receptor and nucleic acids encoding same
WO2002002625A3 (en) Novel fibroblast growth factors and nucleic acids encoding same
WO2001074856A3 (en) Wnt-7b-like polypeptides and nucleic acids encoding same
WO2001070978A3 (en) Polypeptides and nucleic acids encoding same
WO2001062928A3 (en) Polypeptides and nucleic acids encoding same
WO2001061009A3 (en) Polypeptides and nucleic acids encoding same
WO2003025147A3 (en) Novel polynucleotides and proteins encoded thereby
WO2001044473A3 (en) Polypeptides and nucleic acids encoding same
WO2001036638A8 (en) Polypeptides and nucleic acids encoding same
WO2000061754A3 (en) Human proteins and polynucleotides encoding them
WO2000070046A3 (en) Secreted polypeptides and corresponding polynucleotides
WO2001036635A3 (en) Neurite outgrowth-promoting factor homologue and nucleic acids encoding same
WO2001068851A3 (en) Polypeptides and nucleic acids encoding same
WO2001085767A3 (en) Human proteins polynucleotides encoding them and methods of using the same
WO2001023561A3 (en) Novel polynucleotides encoding proteins containing thrombospondin type 1 repeats
WO2002102990A3 (en) Fibroblast growth factor and nucleic acid encoding same
WO2001025429A3 (en) Hepatoma-derived growth factor-like proteins, polynucleotides encoding them and methods of use
WO2003040345A3 (en) Type 2 cytokine receptor and nucleic acids encoding same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US US US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002316291

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2446285

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003506444

Country of ref document: JP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 52/2002 UNDER (30) REPLACE "NOT FURNISHED" BY "60/385,173"

WWE Wipo information: entry into national phase

Ref document number: 2002746584

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002746584

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载